CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.

Ignacio Melero Bermejo Miguel F Sanmamed Javier Glez-Vaz Carlos Luri-Rey Jun Wang Lieping Chen

Published in: Cancer discovery (2022)

CD137 (4-1BB) is a costimulatory receptor of T and natural killer lymphocytes whose activity can be exploited in cancer immunotherapy strategies as discovered 25 years ago. Following initial attempts that met unacceptable toxicity, new waves of constructs acting agonistically on CD137 are being developed in patients, offering signs of clinical and pharmacodynamic activity with tolerable safety profiles.

Keyphrases

nk cells
end stage renal disease
newly diagnosed
ejection fraction
growth factor
prognostic factors
oxidative stress
peripheral blood
tyrosine kinase
recombinant human
patient reported